1.2M
Downloads
966
Episodes
Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com
Episodes
Monday Jun 16, 2025
Monday Jun 16, 2025
Efficacy and Safety of Xeligekimab in AS
Sonelokimab in PsA
Seronegative Arthritis Breakthroughs
Novel Therapies in Axial Spondyloarthritis
Monday Jun 16, 2025
Monday Jun 16, 2025
JAK Inhibitors: The Latest from the JAK-pot Study
Does Abatacept Buy You Time Off RA?
How to Properly Use Steroids in Early RA: Oral vs Parenteral
All Rheumatoid Arthritis is Not the Same
Jekyll and Hyde: which RA-ILD is it?
RA treatment: A Constant State of Evolution
Monday Jun 16, 2025
Monday Jun 16, 2025
Who/When to Treat Clinically Suspect Arthralgia
Thoughtful, Effective RA Care Should be Guided by Need —Not Age
The Impact of Biologics on Methotrexate Adherence
Jokes Aside: The Impact of Laughter in RA
JAK Safety Update
Why is RA Difficult to Treat?
DMARD Combinations in RA Treatment
Increased Risk of VTE in RA: Lessons Learned from 40 Years of Data
ALTO: Long-term Outcomes of APIPPRA
Monday Jun 16, 2025
Monday Jun 16, 2025
Efficacy and Safety of Xeligekimab in AS
Lessons on Uveitis and AxSpA
Difficult to Treat Axial Spondyloarthritis
MRI Lesions in Early axSpA vs Non-axSpA
Emerging Therapies in Axial Spondyloarthritis
Chronic Pain in AxSpA Beyond Fibromyalgia
Novel Therapies in Axial Spondyloarthritis
GLP 1 Receptor Agonists in axSpA Patients
Monday Jun 16, 2025
Monday Jun 16, 2025
Difficult to Treat Psoriatic Arthritis
Less or more frequent dosing in PsA?
Complex-to-Manage PsA: The GRAPPA Framework and Definition
Biologic Switching in PsA
Decoding Difficult to Treat PsA
Deucravacitinib in Psoriatic Arthritis: A New Oral Option with Dual Impact
Monday Jun 16, 2025
Monday Jun 16, 2025
EULAR 2025 - Day 1 podcasts
Sonelokimab in PsA
Seronegative Arthritis Breakthroughs
Using Combination csDMARDs in PsA
Deucravacitinib's Place in the PsA Treatment Algorithm?
Monday Jun 16, 2025
Monday Jun 16, 2025
Biologic Switching in PsA
Decoding Difficult to Treat PsA
Deucravacitinib in Psoriatic Arthritis: A New Oral Option with Dual Impact
GLP 1 Receptor Agonists in axSpA Patients
Jekyll and Hyde: which RA-ILD is it?
RA treatment: A Constant State of Evolution
Saturday Jun 14, 2025
Saturday Jun 14, 2025
Difficult to Treat Psoriatic Arthritis
Less or more frequent dosing in PsA?
Complex-to-Manage PsA: The GRAPPA Framework and Definition
Emerging Therapies in Axial Spondyloarthritis
Chronic Pain in AxSpA Beyond Fibromyalgia
Novel Therapies in Axial Spondyloarthritis
JAK Inhibitors: The Latest from the JAK-pot Study
Does Abatacept Buy You Time Off RA?
How to Properly Use Steroids in Early RA: Oral vs Parenteral
All Rheumatoid Arthritis is Not the Same
Saturday Jun 14, 2025
Saturday Jun 14, 2025
Catch up on the biggest breakthroughs, standout sessions, and expert insights from the fourth day of EULAR 2025. Join us live as we break down the key highlights and what they mean for the future of rheumatology.
Friday Jun 13, 2025
Friday Jun 13, 2025
Deucravacitinib's Place in the PsA Treatment Algorithm?
Lessons on Uveitis and AxSpA
Difficult to Treat Axial Spondyloarthritis
MRI Lesions in Early axSpA vs Non-axSpA
JAK Safety Update
Why is RA Difficult to Treat?
DMARD Combinations in RA Treatment
Increased Risk of VTE in RA: Lessons Learned from 40 Years of Data
ALTO: Long-term Outcomes of APIPPRA